| Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis ZD Nassar, CY Mah, J Dehairs, IJG Burvenich, S Irani, MM Centenera, ... Elife 9, e54166, 2020 | 127 | 2020 |
| Peri‐prostatic adipose tissue: the metabolic microenvironment of prostate cancer ZD Nassar, AT Aref, D Miladinovic, CY Mah, GV Raj, AJ Hoy, LM Butler BJU international 121, 9-21, 2018 | 73 | 2018 |
| ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer MM Centenera, JS Scott, J Machiels, ZD Nassar, DC Miller, I Zinonos, ... Cancer research 81 (7), 1704-1718, 2021 | 63 | 2021 |
| Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition LM Butler, CY Mah, J Machiels, AD Vincent, S Irani, SM Mutuku, ... Cancer research 81 (19), 4981-4993, 2021 | 60 | 2021 |
| Endocrine disruptor compounds—a cause of impaired immune tolerance driving inflammatory disorders of pregnancy? JE Schjenken, ES Green, TS Overduin, CY Mah, DL Russell, ... Frontiers in endocrinology 12, 607539, 2021 | 45 | 2021 |
| LC3-associated phagocytosis (LAP): a potentially influential mediator of efferocytosis-related tumor progression and aggressiveness PF Asare, E Roscioli, PR Hurtado, HB Tran, CY Mah, S Hodge Frontiers in Oncology 10, 1298, 2020 | 40 | 2020 |
| Lipogenic effects of androgen signaling in normal and malignant prostate CY Mah, ZD Nassar, JV Swinnen, LM Butler Asian Journal of Urology 7 (3), 258-270, 2020 | 36 | 2020 |
| Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by HSP90 inhibition ZD Nassar, CY Mah, MM Centenera, S Irani, MC Sadowski, JS Scott, ... Molecular Cancer Research 18 (10), 1500-1511, 2020 | 20 | 2020 |
| The mTORC1 complex in pre-osteoblasts regulates whole-body energy metabolism independently of osteocalcin P Tangseefa, SK Martin, PY Chin, J Breen, CY Mah, PA Baldock, ... Bone research 9 (1), 10, 2021 | 6 | 2021 |
| Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer JA Hinneh, JL Gillis, CY Mah, S Irani, RK Shrestha, NK Ryan, E Atsushi, ... British Journal of Cancer 129 (8), 1350-1361, 2023 | 3 | 2023 |
| Abstract PO-036: ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress RK Shrestha, S Townley, A Hanson, M Pickering, ZD Nassar, CY Mah, ... Cancer Research 80 (23_Supplement), PO-036-PO-036, 2020 | 3 | 2020 |
| Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer CY Mah, ADT Nguyen, T Niijima, M Helm, J Dehairs, FJ Ryan, N Ryan, ... British Journal of Cancer 130 (5), 741-754, 2024 | 2 | 2024 |
| Integration of Multiple Spatial-Omics Modalities Reveals Unique Insights into Molecular Heterogeneity of Prostate Cancer W Zhang, X Spotbeen, S Vanuytven, S Kint, T Sarretto, F Socciarelli, ... bioRxiv, 2023.08. 28.555056, 2023 | 2 | 2023 |
| Lipid elongation in prostate cancer: an androgen regulated process and a novel therapeutic target ZD Nassar, MM Centenera, J Machiels, I Zinonos, A Hanson, K Bloch, ... Oncology Abstracts 1, 2019 | 2 | 2019 |
| ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis RK Shrestha, ZD Nassar, AR Hanson, R Iggo, SL Townley, J Dehairs, ... Cancer Research 84 (14), 2313-2332, 2024 | | 2024 |
| Uncovering a novel role of peroxisomal β-oxidation in advanced, treatment-resistant prostate cancer CY Mah, AD Nguyen, T Niijima, M Helm, J Dehairs, FJ Ryan, N Ryan, ... Cancer Research 83 (7_Supplement), 1157-1157, 2023 | | 2023 |
| ACSM1 and ACSM3 regulate prostate cancer fatty acid metabolism to promote tumour growth and constrain ferroptosis R Shrestha, ZD Nassar, AR Hanson, R Iggo, SL Townley, J Dehairs, ... bioRxiv, 2022.10. 13.511039, 2022 | | 2022 |
| Targeting fatty acid metabolism in prostate cancer CY Mah | | 2021 |
| DECR1: The rate limiting enzyme of polyunsaturated fatty acid metabolism and a novel therapeutic target in prostate cancer CY Mah, ZD Nassar, IJ Burvenich, S Irani, MM Centenera, M Moldovan, ... Cancer Research 80 (16_Supplement), 237-237, 2020 | | 2020 |
| Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis LM Butler, CY Mah, J Dehairs, A Vincent, S Mutuku, X Spotbeen, R Das, ... Cancer Research 80 (16_Supplement), 2076-2076, 2020 | | 2020 |
